In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Neena Brizmohun

Executive Editor

Neena has been covering regulatory, business and market access developments that impact pharmaceutical and medical device companies since 1997. She explores the challenges and opportunities that developments worldwide introduce for industry and regulators. Her areas of expertise include regulatory schemes for getting products to market faster. Neena's other specialist areas include new medicines coming to market in the EU, pricing and reimbursement, clinical trials, real-world evidence, post-marketing safety monitoring, transparency policies relating to the publication of trial data, and global harmonization initiatives for pharma and medtech.

Latest From Neena Brizmohun

French Regulator At Odds With EMA Over Safety Restrictions For Pseudoephedrine

The product information for all pseudoephedrine-containing medicines in the EU will need to be updated, the European Medicines Agency said today.

Europe France

Drug Candidates For NASH & Epilepsy Disorder Secure EMA PRIME Designations

The developers of survodutide and elsunersen will be able to benefit from the early and enhanced support that the European Medicines Agency offers through its priority medicines scheme.

Europe Research & Development

New Zealand Seeks Funding Applications For Rare Disorder Drugs

Applications from drug companies should also include a commercial proposal, says Pharmac.

Rare Diseases Cost Effectiveness

England’s NICE Considers Challenges In Assessing Cost Effectiveness Of Alzheimer’s Drugs

Health technology assessment institute NICE is scheduled to appraise Eisai/Biogen’s lecanemab and Eli Lilly’s donanemab next year.

Cost Effectiveness Neurology

UK Clinical Trials Showing Signs Of Recovery But Global Ranking Still Poor

While things are starting to look up for the commercial clinical trial ecosystem in the UK, more progress is needed to improve industry’s confidence in the country as a destination for research, especially revenue-generating Phase III trials.

United Kingdom Clinical Trials

New EU Approvals

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Jaypirca, Eli Lilly’s treatment for relapsed or refractory mantle cell lymphoma.

Europe Approvals
See All
UsernamePublicRestriction

Register